ECDC awards 77 M€ to strengthen EU/EEA Member States’ capacities to detect and identify SARS-CoV-2 variants
ECDC has awarded more than 77 M€ to 24 EU/EEA countries to strengthen whole genome sequencing and RT-PCR infrastructures within the countries’ national public health programmes.
ECDC supports EU/EEA Member States in rapid detection of SARS-CoV-2 variants
ECDC and the European Commission’s Directorate-General for Health and Food Safety (DG SANTE) have launched a number of activities to help strengthen EU/EEA Member States’ capacity for detection of SARS-CoV-2 variants in the shorter and longer term. These activities are one of five action areas of the ‘HERA Incubator’, a new EU bio-defence preparedness plan against SARS-CoV-2 variants launched by the European Commission on 17 February 2021.
Seventh external quality assessment scheme for Listeria monocytogenes typing
This report presents the results of the seventh round of the external quality assessment (EQA-7) scheme for Listeria monocytogenes (L. monocytogenes) typing organised for national public health reference laboratories (NPHRLs) providing data to the Food- and Waterborne Diseases and Zoonoses Network (FWD-Net) managed by ECDC.
Tenth external quality assessment scheme for Salmonella typing
ECDC is supporting a large number of targeted External Quality Assessment (EQA) schemes with voluntary participation by reference or primary laboratories, which are active members of EU surveillance networks.
Laboratory standard operating procedure for detecting sporadic Creutzfeldt-Jakob disease using Real- Time Quaking-Induced Conversion (RT-QuIC) assay
This document provides laboratories with a single protocol for producing recombinant full-length hamster prion protein and using it to perform the Real-Time Quaking-Induced Conversion assay (RT-QuIC), which can distinguish sporadic Creutzfeldt-Jakob disease (sCJD) from variant Creutzfeldt-Jakob disease (vCJD).
Sequencing of SARS-CoV-2 - first update
This technical guidance aims to provide guidelines to laboratories and relevant stakeholders in the European Union (EU), European Economic Area (EEA) and other countries in the WHO European region in making decisions on establishing sequencing capacities and capabilities, in making decisions on which technologies to use and/or in deciding on the role of sequencing for SARS-CoV-2 diagnostics, research, outbreak investigations and surveillance.
ECDC rapid assessment of laboratory practices and needs related to COVID-19
This report assesses the current status of the EU/EEA and the UK COVID-19 laboratory response based on a short survey sent to all Member States and the UK.
Impact of the COVID-19 pandemic on tuberculosis laboratory services in Europe
V. Nikolayevskyy, Y. Holicka, D. van Soolingen, M. J. van der Werf, C. Ködmön, E. Surkova, D. Hillemann, R. Groenheit and D. Cirillo
Variable sensitivity in molecular detection of SARS-CoV-2 in European Expert Laboratories: External Quality Assessment, June - July 2020
C. Fischer, R. Mögling, A. Melidou, A. Kühne, E. F. Oliveira-Filho, T. Wolff, J. Reiche, E. Broberg, A. Meijer, K. Leitmeyer, J. F. Drexler and C. Reusken